EP1596849A1 - Controlled release pharmaceutical compositions of tamsulosin - Google Patents

Controlled release pharmaceutical compositions of tamsulosin

Info

Publication number
EP1596849A1
EP1596849A1 EP03780445A EP03780445A EP1596849A1 EP 1596849 A1 EP1596849 A1 EP 1596849A1 EP 03780445 A EP03780445 A EP 03780445A EP 03780445 A EP03780445 A EP 03780445A EP 1596849 A1 EP1596849 A1 EP 1596849A1
Authority
EP
European Patent Office
Prior art keywords
tamsulosin
composition
cellulose
mixtures
enteric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03780445A
Other languages
German (de)
English (en)
French (fr)
Inventor
Girish Kumar Jain
Seetharaman Sritharan
Ashok Rampal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Publication of EP1596849A1 publication Critical patent/EP1596849A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes

Definitions

  • the technical field of the invention relates to controlled release pharmaceutical compositions of tamsulosin or pharmaceutically acceptable salts thereof. More particularly, the invention relates to a controlled release individual unit or multiple unit formulation comprising a spherical core obtained by adding a release controlling agent to a mixture of tamsulosin and a spheronizing agent. The invention also relates to methods of preparing such formulations. Background of the Invention
  • modified release formulations The need to improve the clinical results of modified release formulations is well documented in the prior art. This is particularly important for drugs that have short half- lives, region specific absorption, produce gastric irritation, or have other side effects at high plasma concentrations.
  • One of the most common methods of achieving modified drug release involves the use of monolithic systems designed to have modified release characteristics. These monolithic systems vary from osmotic drug delivery systems to bioerodible or non-erodible matrix based systems.
  • the final dosage form consists of a collection of the multiple units, compressed into a tablet, or filled into a capsule or sachet.
  • the individual units When administered, the individual units are dispersed freely into the gastrointestinal contents, avoiding the high local concentration of drug which may lead to irritation of gastrointestinal mucosa.
  • the performance of the dosage form is independent of inter- and intra-patient variability in gastric emptying time because of the small size of the individual units that make up the system.
  • Multiple unit dosage forms possess large surface area, which promotes complete and uniform absorption, minimize peak plasma fluctuations and thus reduce the potential for systemic side effects. Further advantages of these dosage forms are that high local concentrations of the active substance in the gastrointestinal system is avoided, due to the units being distributed freely throughout the tract, less variation in absorption is observed and there is reproducibility in the dissolution characteristics.
  • Drug release from such extended release multiple units is controlled either by diffusion of a coating or by erosion of the coating by a process dependent on enzymes or pH.
  • the erodible coatings involve the use of enteric polymers, which rapidly erode in the intestines.
  • roller compaction Extrusion/spheronization is a multistep process used to make uniformly sized particles. It is used primarily to produce multiparticulates for controlled or sustained release applications. This process is also used to increase the bulk density, improve flow properties and reduces the problem of dust usually encountered with low-density, finely divided active and excipient powders.
  • the general process involves separate processes of wet massing, followed by extrusion of this wet mass into cylindrical segments and subsequent spheronization of these segments to round off these cylindrical segments into spherical particles. Extrusion involves forcing the wet mass through dies and shaped into cylindrical particles with uniform diameter. The extrudate particles break at similar lengths.
  • Tamsulosin 5-[(2R)-2-[[2-(2-ethoxy-phenoxy) ethyl] amino] propyl]-2-methoxy benzene sulfonamide, is an ⁇ i-adrenoceptor blocking agent, exhibiting selectivity for ⁇ i- receptors in the human prostate. It is disclosed in EP 34432 and U.S. Patent No. 4,731,478 as a pharmaceutically active substance having alpha-adrenergic blocking activity that is useful for treatment of cardiac insufficiencies and benign prostatic hyperplasia. The pharmacokinetic studies of tamsulosin show that it is absorbed from the intestine and is almost completely bioavailable.
  • U.S. Patent No. 4,772,475 discloses an oral pharmaceutical controlled release multiple unit formulation in which the individual units comprise a granulation product of a release controlling agent, physiologically active substance and units-forming substance (s).
  • the patent emphasizes that the unit-forming substance (crystalline cellulose) should at least be 50% by weight.
  • the drug containing units of this invention have high mechanical strength and can control dissolution rate without enteric coating.
  • the object should be to develop a composition, which releases the drug gradually in the intestine where it is completely absorbed.
  • enteric-coated, controlled release formulation of tamsulosin provides release at the desired site.
  • the controlled release formulation can be prepared with less than 50% w/w of a spheronizing agent.
  • a controlled release pharmaceutical composition of tamsulosin that includes a spheroid core.
  • the core includes tamsulosin, about 10% to about 45% w/w of a spheronizing agent and one or more rate controlling polymers; and an outer enteric coating layer.
  • the enteric coating is placed over the core.
  • the core may include one or more of sugar, a non-pareil seed, microcrystalline cellulose, celphere, sand silicon dioxide, glass, plastic, polystyrene, hydroxypropyl methylcellulose.
  • the sugar may include one or more of glucose, mannitol, lactose, xylitol, dextrose, and sucrose.
  • the core may include one or more of an insoluble material, a soluble material, and a swellable material.
  • Embodiments of the pharmaceutical composition are prepared by a spheronization process.
  • the spheronizing agent may be microcrystalline cellulose.
  • the tamsulosin may include one or more of free base, pharmaceutically acceptable salts and isomers of tamsulosin.
  • the pharmaceutically acceptable salts of tamsulosin may be one or more of hydrochloride, hydroiodide, hydrobromide, hydrogen fumarate, and the like.
  • the pharmaceutically acceptable salt of tamsulosin may be hydrochloride.
  • the pharmaceutical composition may contain a concentration of from about 0.03% to about 0.33% by weight of tamsulosin.
  • the rate controlling polymer may include one or more of enteric polymers, water insoluble polymers, water-soluble polymers, alkaline metal salts of a higher fatty acid, waxes, and mixtures thereof.
  • the rate controlling polymer may be present in the pharmaceutical composition at a concentration of from about 20% to about 90% by weight.
  • the enteric polymer may include one or more of hydroxylpropylmethyl cellulose phthalate, cellulose acetate phthalate, methacrylic acid, and ethyl acrylate copolymer. h particular, the enteric polymer may include one or more of methacrylic acid and ethyl acrylate copolymer.
  • the wax may include one or more of hydro genated vegetable oils, esters of long chain fatty acids, long chain fatty acids, and mixtures thereof. The wax may include one or more of glyceryl monos.tearate and stearic acid.
  • the water soluble polymer may include one or more of polyvinylpyrrolidone, hydroxypropyl cellulose, carboxymethylcellulose sodium, liydroxypropylmethyl cellulose, hydroxyethyl cellulose, methyl cellulose, and mixtures thereof.
  • the water insoluble polymer may include one or more of ethyl cellulose, cellulose acetate, methacrylic acid-acrylic acid copolymers with quaternary ammonium groups, and mixtures thereof.
  • the alkaline metal salts of higher fatty acid may include one or more of magnesium stearate, zinc stearate, calcium stearate, and mixtures thereof.
  • the alkaline metal salt of higher fatty acid may include magnesium stearate.
  • the spheroid core may include one or more of pharmaceutically acceptable excipients.
  • the pharmaceutically acceptable excipients may include one or more of plasticizers, diluents, colorants and flavoring agents.
  • the enteric coating may include one or more of hydroxypropyl methylcellulose phthalate, polyvinyl phthalate, cellulose acetate phthalate, copolymers of acrylic and methacrylic acid and mixtures thereof.
  • the enteric coating may also have one or more of alkalizing agents, plasticizer, tack-modifiers and opacifiers.
  • the pharmaceutical composition may be formulated into capsules, sachets, and tablets.
  • a process for the preparation of a controlled release pharmaceutical composition of tamsulosin includes providing spherical cores that includes tamsulosin, a spheronizing agent and one or more of rate controlling polymers; and coating the spheroid cores with an enteric polymer.
  • the core may be prepared by extrusion-spheronization.
  • the extrasion-spheronization process may include granulating tamsulosin, spheronizing agent and one or more rate controlling polymers, extruding the granulated mixture to obtain extrudates, spheronizing the extradates to obtain spherical cores, drying the spheroid cores; and coating the spheroid cores with an enteric polymer.
  • the tamsulosin may include one or more of free base, pharmaceutically acceptable salts and isomers of tamsulosin.
  • the pharmaceutically acceptable salts of tamsulosin maybe one or more of hydrochloride, hydroiodide, hydrobromide, hydrogen fumarate, and the like.
  • the pharmaceutically acceptable salt of tamsulosin may be hydrochloride.
  • the pharmaceutical composition may contain a concentration of from about 0.03% to about 0.33% by weight of tamsulosin.
  • the rate controlling agent may include one or more of enteric polymers, water insoluble polymers, water-soluble polymers, alkaline metal salts of a higher fatty acid, waxes, and mixtures thereof at a concentration of from about 20% to about 90% by weight of the composition.
  • the enteric polymer may include one or more of hydroxylpropylmethyl cellulose phthalate, cellulose acetate phthalate, methacrylic acid, and ethyl acrylate copolymer. h particular, the enteric polymer may include one or more of methacrylic acid and ethyl acrylate copolymer.
  • the wax may include one or more of hydro genated vegetable oils, esters of long chain fatty acids, long chain fatty acids, and mixtures thereof. In particular, the wax may include one or more of glyceryl monostearate and stearic acid.
  • the water soluble polymers may include one or more of polyvinylpyrrolidone, hydroxypropyl cellulose, carboxymethylcellulose sodium, liydroxypropylmethyl cellulose, hydroxyethyl cellulose, methyl cellulose, and mixtures thereof.
  • the water insoluble polymers may include one or more of ethyl cellulose, cellulose acetate, methacrylic acid-acrylic acid copolymers with quaternary arrimonium groups, and mixtures thereof.
  • the alkaline metal salts of higher fatty acid may include one or more of magnesium stearate, zinc stearate, calcium stearate and mixtures thereof.
  • the alkaline metal salt of higher fatty acid may include magnesium stearate.
  • the spheroid core may include one or more of pharmaceutically acceptable excipients.
  • the pharmaceutically acceptable excipients may include one or more of plasticizers, diluents, colorants and flavoring agents.
  • the enteric coating may include one or more of hydroxypropyl methylcellulose phthalate, polyvinyl phthalate, cellulose acetate phthalate, copolymers of acrylic and methacrylic acid and mixtures thereof.
  • the enteric coating may also have one or more of alkalizing agents, plasticizer, tack-modifiers and opacifiers.
  • the pharmaceutical composition may be formulated into capsules, sachets, and tablets. hi another general aspect there is provided a process for the preparation of a controlled release pharmaceutical composition of tamsulosin.
  • the process includes granulating tamsulosin and spheronizing agent with dispersion of one or more of rate controlling polymers, extruding the granulates to form extrudates using an extruder, spheronizing the extrudates until spherical cores are formed; and coating the spheroid cores with an enteric polymer.
  • the tamsulosin may include one or more of free base, pharmaceutically acceptable salts and isomers of tamsulosin.
  • the pharmaceutically acceptable salts of tamsulosin may be one or more of hydrochloride, hydroiodide, hydrobromide, hydrogen fumarate, and the like.
  • the pharmaceutically acceptable salt of tamsulosin may be hydrochloride.
  • the pharmaceutical composition may contain a concentration of from about 0.03% to about 0.33% by weight of tamsulosin.
  • the rate controlling agent may include one or more of enteric polymers, water insoluble polymers, water-soluble polymers, alkaline metal salts of a higher fatty acid, waxes, and mixtures thereof at a concentration of from about 20% to about 90%> by weight of the composition.
  • the enteric polymer may include one or more of hydroxylpropylmethyl cellulose phthalate, cellulose acetate phthalate, methacrylic acid, and ethyl acrylate copolymer. i particular, the enteric polymer may include one or more of methacrylic acid and ethyl acrylate copolymer.
  • the wax may include one or more of hydro genated vegetable oils, esters of long chain fatty acids, long chain fatty acids, and mixtures thereof.
  • the wax may include one or more of glyceryl monostearate and stearic acid.
  • the water soluble polymers may include one or more of polyvinylpyrrolidone, hydroxypropyl cellulose, carboxymethylcellulose sodium, hydroxypropyhnethyl cellulose, hydroxyethyl cellulose, methyl cellulose, and mixtures thereof.
  • the water insoluble polymers may include one or more of ethyl cellulose, cellulose acetate, methacrylic acid-acrylic acid copolymers with quaternary arrrmonium groups, and mixtures thereof.
  • the alkaline metal salts of higher fatty acid may include one or more of magnesium stearate, zinc stearate, calcium stearate and mixtures thereof.
  • the alkaline metal salt of higher fatty acid may include magnesium stearate.
  • the spheroid core may include one or more of pharmaceutically acceptable excipients.
  • the pharmaceutically acceptable excipients may include one or more of plasticizers, diluents, colorants and flavoring agents.
  • the enteric coating may include one or more of hydroxypropyl methylcellulose phthalate, polyvinyl phthalate, cellulose acetate phthalate, copolymers of acrylic and methacrylic acid and mixtures thereof.
  • the enteric coating may also have one or more of alkalizing agents, plasticizer, tack-modifiers and opacifiers.
  • the pharmaceutical composition may be formulated into capsules, sachets, and tablets.
  • a method for preparing a controlled release pharmaceutical composition includes providing a core having a coating, forming individual units, and forming the dosage form by combining one or more individual units.
  • Embodiments of the method of preparing a controlled release multiple unit dosage form may include one or more of the following features, including any one or more of the features described above.
  • Combining one or more individual units may include filling the individual units into a capsule or sachet or compressing the individual units into a tablet.
  • a method of treating symptoms of benign prostatic hyperplasia includes administering a controlled-release pharmaceutical composition of tamsulosin, which includes a spheroid core.
  • This core includes tamsulosin, about 10% to about 45% w/w of a spheronizing agent, and one or more ratecontrolling polymers.
  • the core is then coated by an enteric coating.
  • Embodiments of the method may contain any one or more features described above.
  • the details of one or more embodiments of the inventions are set forth in the description below. Other features, objects and advantages of the inventions will be apparent from the description and claims.
  • the present invention relates to controlled release individual unit or multiple unit formulation comprising an enteric coated spherical core, wherein the core comprises tamsulosin, about 10% to about 45% w/w of a spheronizing agent and rate controlling polymers.
  • Tamsulosin may comprise free base, pharmaceutically acceptable salts or isomers of tamsulosin thereof.
  • the pharmaceutically acceptable salts may include hydrochloride, hydroiodide, hydrobromide, hydrogen fumarate, and the like. Tamsulosin constitutes about 0.03 to about 0.33% by weight of the formulation.
  • the spheronizing agent may comprise any pharmaceutically acceptable material, which may be spheronized together with the active ingredient to form spheroid cores.
  • the most commonly used spheronizing agent is microcrystalline cellulose.
  • the microcrystalline cellulose employed may be, for example, Avicel® PH 101 or Avicel® PH 102 commercially available from FMC Corporation.
  • the spheronizing agent may be present in an amount ranging from about 10% to about 45% by weight of the formulation.
  • the rate controlling agent may include one or more of enteric polymers, water insoluble polymers, water-soluble polymers, alkaline metal salts of a higher fatty acid, waxes, and mixtures thereof.
  • Suitable enteric polymers include those known in the art, such as hydroxypropyl methyl cellulose acetate phthalate, hydroxypropyl methyl cellulose acetate succinate, polyvinyl acetate phthalate, polymethylacrylates and copolymers of acrylic and methacrylic acid (commercially available under the trade name of Eudragit®), for example, Eudragit L30D-55 (anionic aqueous polymer dispersion of methacrylic acid - ethyl acrylate copolymer), Eudragit L100-55 (Spray-dried Eudragit L30D-55 which can be reconstituted as aqueous dispersion), Eudragit LI 00 (anionic polymer powder solubilizing above pH 6.0) and Eudragit S100 (anionic polymer powder solubilizing above pH 7.0).
  • Eudragit L30D-55 anionic aqueous polymer dispersion of methacrylic acid - ethyl acrylate copolymer
  • Suitable waxes include one or more of hydrogenated vegetable oils, esters of long chain fatty acids, long chain fatty acids such as stearic acid and oleic acid, and mixtures thereof.
  • Suitable water-insoluble polymers include one or more of ethyl cellulose, cellulose acetate, copolymers of polyethylene and vinyl acetate, methacrylic acid methyl methacrylate copolymers with quaternary ammonium groups such as those sold under the trade name Eudragit® RL, Eudragit® RS and Eudragit® NE, and the like.
  • Suitable examples of the alkaline metal salts of a higher fatty acid include one or more of magnesium stearate, zinc stearate, calcium stearate, and the like.
  • Suitable water-soluble polymers may include one or more of polyvinylpyrrolidone, carboxymethylcellulose sodium, hydroxylpropyl cellulose, hydroxypropyl methylcellulose, hydroxyethyl cellulose, methylcellulose, and mixtures thereof.
  • the rate controlling polymers may comprise about 20 to about 90% by weight of the formulation.
  • the rate controlling polymers in accordance with this invention may also act as binder and may be added as such or dissolved or dispersed in an appropriate solvent system and the resulting solution or dispersion is then used to granulate the active agent. The resulting granulated mass may then be subjected to extrusion and spheronization. This method of incorporation allows the rate controlling polymers to more effectively retard drug release.
  • the spheroid cores may also contain other pharmaceutically acceptable excipients.
  • the other pharmaceutically acceptable excipients as used herein include plasticizers, diluents, colorants, and flavoring agents.
  • Suitable diluents include one or more of lactose, starch, sugar alcohols, sucrose and mixtures thereof.
  • the controlled release composition according to this invention may be prepared by: a. granulating tamsulosin, spheronizing agent and rate controlling polymers with water, b. extruding the granulated mixture to give extrudates; and c. spheronizing the extrudates until spherical cores are formed.
  • granulation according to step a) may be carried out with a dispersion of rate controlling polymers.
  • Extrusion maybe carried out in any of the extruders such as screw-feed extruders and gravity-feed extruders such as cylindrical roll or gear roll and piston-feed extruders.
  • the pharmaceutical composition according to the present invention further includes an enteric coating over the spheroid core.
  • This coating will substantially eliminate dissolution in the acidic environment of the stomach but will dissolve sufficiently to permit release in a controlled manner over an extended period in the intestine.
  • enteric coatings include one or more of neutralized hydroxypropyl methylcellulose phthalate (HPMCP) coating, beeswax, glyceryl monostearate, shellac and cellulose, shellac and stearic acid; neutral copolymer of methacrylic acid and methacrylic acid methyl ester (Eudragit®) or a neutral copolymer of polymethacrylic acid esters containing metallic stearates.
  • HPMCP neutralized hydroxypropyl methylcellulose phthalate
  • beeswax glyceryl monostearate
  • shellac and cellulose shellac and stearic acid
  • EUdragit® neutral copolymer of methacrylic acid and methacrylic acid methyl ester
  • the other enteric coating polymers known in the art may also be employed, including one or more of polyvinyl acetate phthalate, cellulose acetate phthalate, cellulose acetate succinate and the like.
  • enteric coating materials are acidic in nature and hence may cause chemical instability when in contact with active ingredient. However, this can be avoided by using suitable alkalizing agents like sodium hydroxide, potassium hydroxide, calcium carbonate, sodium carboxymethylcellulose, magnesium oxide and magnesium hydroxide.
  • the enteric coating may also contain a plasticizer, which may be one or more of citrate, triacetin, diethyl phthalate, dibutyl phthalate, polyethylene glycol, propylene glycol, glycerol, tributyl citrate, and the like.
  • the enteric coating may also include anti-adherent or tack-modifiers as an inert aid in the stability of coating process. Suitable tack-modifier may include one or more of talc, kaolin or colloidal anhydrous silica.
  • the coating may also include an opacifier such as titanium dioxide.
  • the enteric coating layer can be formed on the surface of the spheroid cores, using conventional coating methods, such as fluidized or pan coating.
  • compositions prepared according to the invention may be filled into capsules, sachets or compressed into tablets using conventional pharmaceutical techniques.
  • Tamsulosin hydrochloride is dissolved in water and the solution is used to granulate microcrystalline cellulose, in a mixer.
  • step 1 Granulate of step 1 is dried in a fluidized bed dryer at 60°C and sieved to a particle size of less than about 600 ⁇ . 3.
  • Magnesium stearate/ glyceryl mono stearate/ stearic acid and starch are sieved to a particle size of less than about 600 ⁇ and mixed with granulate of step 2 in a mixer.
  • step 3 is granulated with the dispersion of methacrylic acid-ethyl acrylate copolymer (Eudragit L30D 55) in a rotary mixer grinder. In Example 3, same blend is further granulated by 10% solution of povidone in water. 5. Granulate of Step 4 is extruded through a bore of inner diameter of 1mm.
  • step 5 The extrudates of step 5 are spheronized-using spheronizer fitted with plate of 3.25 mm pitch.
  • Spherical cores obtained in step 6 are dried in fluidized bed dryer at 60°C for one hour.
  • Enteric coating dispersion of Eudragit L100: 55 is prepared by dispersing enteric coating materials in water.
  • the spherical cores of step 7 are coated with the dispersion of step 8, to a weight gain of about 3.33%> w/w. 10.
  • the coated cores of step 9 are filled in capsules.
  • Example 1 The resulting capsules of Example 1 were compared with FLOMAX capsules (containing 0.4mg tamsulosin marketed by Boehringer Ingelheim) for in vitro release of tamsulosin.
  • the dissolution studies were performed using USP Apparatus II at 50 rpm in 500ml phosphate buffer pH 6.8. The results are shown in Table 1.
  • Table 1 Comparative in vitro release data of tamsulosin from capsules (of Example 1) and FLOMAX capsules (of Boehringer Ingelheim) using USP dissolution apparatus 11/ 500 ml/ pH 6.8 phosphate buffer/ 50 rpm

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP03780445A 2002-12-20 2003-12-18 Controlled release pharmaceutical compositions of tamsulosin Withdrawn EP1596849A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
INDE12922002 2002-12-20
IN1292DE2002 IN192381B (ja) 2002-12-20 2002-12-20
PCT/IB2003/006072 WO2004056354A1 (en) 2002-12-20 2003-12-18 Controlled release pharmaceutical compositions of tamsulosin

Publications (1)

Publication Number Publication Date
EP1596849A1 true EP1596849A1 (en) 2005-11-23

Family

ID=32676755

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03780445A Withdrawn EP1596849A1 (en) 2002-12-20 2003-12-18 Controlled release pharmaceutical compositions of tamsulosin

Country Status (9)

Country Link
EP (1) EP1596849A1 (ja)
JP (1) JP2006512358A (ja)
CN (1) CN1744889A (ja)
AU (1) AU2003288604A1 (ja)
BR (1) BR0317567A (ja)
CA (1) CA2511208A1 (ja)
IN (1) IN192381B (ja)
RU (1) RU2005121999A (ja)
WO (1) WO2004056354A1 (ja)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004066991A1 (ja) * 2003-01-27 2004-08-12 Yamanouchi Pharmaceutical Co., Ltd. タムスロシンまたはその塩の腸溶性徐放微粒子およびその製造法
EP2112920B1 (en) 2003-06-26 2018-07-25 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
EP1618873B1 (de) * 2004-07-14 2007-06-06 Siegfried Generics International AG Granulat zur kontrollierten Freisetzung von Tamsulosin, enthaltend Alginat
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
JP5457830B2 (ja) 2006-04-03 2014-04-02 オディディ，イサ オルガノゾル被膜を含む制御放出送達デバイス
EP2010162A4 (en) * 2006-04-03 2013-01-09 Isa Odidi COMPOSITION FOR DISPOSING A MEDICINAL PRODUCT
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
WO2008089593A1 (fr) * 2007-01-18 2008-07-31 Standard Chem. & Pharm. Co., Ltd. Preparation de tamsulosine a liberation prolongee et procede de production associe
JP5511663B2 (ja) * 2008-07-01 2014-06-04 沢井製薬株式会社 タムスロシン塩酸塩を含有する球形微粒子の製造方法
CN101695478B (zh) * 2009-10-23 2012-01-18 江苏大学 盐酸坦索罗辛缓释微丸制剂及其制备方法
KR101423237B1 (ko) * 2010-05-04 2014-07-30 주식회사 삼양바이오팜 탐스로신 또는 이의 약학적으로 허용 가능한 염을 포함하는 방출 제어용 약학 조성물, 및 이를 포함하는 경구용 제제
CN103315962A (zh) * 2013-02-01 2013-09-25 北京科信必成医药科技发展有限公司 一种坦索罗辛缓释微丸制剂及其制备方法
CN103142492A (zh) * 2013-02-01 2013-06-12 北京科信必成医药科技发展有限公司 一种缓释微丸制剂及其制备方法
CN103919735B (zh) * 2014-05-04 2018-04-17 翰宇药业（武汉）有限公司 一种盐酸坦索罗辛缓释微丸及其制备方法
ES2555485T1 (es) 2014-05-26 2016-01-04 Galenicum Health S.L. Composiciones farmacéuticas que contienen un agente activo
RU2018142485A (ru) * 2016-05-04 2020-06-04 Эспен Парк Фармасьютикалз, Инк. Отсроченное высвобождение тамсулозина гидрохлорида после перорального введения
EP3473244A1 (en) 2017-10-20 2019-04-24 Veru Inc. Controlled release oral tamsulosin hydrochloride
EP3473245A1 (en) 2017-10-20 2019-04-24 Veru Inc. Controlled release oral tamsulosin hydrochloride
KR20200078146A (ko) * 2018-12-21 2020-07-01 한미약품 주식회사 내산성이 우수한 탐수로신 염산염 함유 제약 조성물 및 이의 제조방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158777A (en) * 1990-02-16 1992-10-27 E. R. Squibb & Sons, Inc. Captopril formulation providing increased duration of activity
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
EP1064938A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmaceutical dosage forms for controlled release producing at least a timed pulse
WO2003039530A1 (en) * 2001-11-07 2003-05-15 Synthon B.V. Tamsulosin tablets

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2004056354A1 *

Also Published As

Publication number Publication date
JP2006512358A (ja) 2006-04-13
RU2005121999A (ru) 2006-01-20
BR0317567A (pt) 2005-11-22
WO2004056354A1 (en) 2004-07-08
CA2511208A1 (en) 2004-07-08
AU2003288604A1 (en) 2004-07-14
CN1744889A (zh) 2006-03-08
IN192381B (ja) 2004-04-10

Similar Documents

Publication Publication Date Title
EP1596849A1 (en) Controlled release pharmaceutical compositions of tamsulosin
JP4789806B2 (ja) パントプラゾール多粒子処方
RU2240786C2 (ru) Пероральные лекарственные формы пролонгированного действия
JP6169411B2 (ja) ゾニサミドの徐放性製剤
US6660382B2 (en) Process for manufacturing coated granules with masked taste and immediate release of the active principle
US6638535B2 (en) Modified release formulations containing a hypnotic agent
JP2720932B2 (ja) 経口投与用アセトアミノフエン錠剤の製造法及びアセトアミノフエン二層錠剤
JP2008303223A (ja) 脈動用量薬剤経口送達システム
JP2001172201A (ja) 経口投与形のための味をマスキングするコーティングとしてのフィルム被覆の使用、経口投与形及びその製造法
CN1356102A (zh) 掩味药物颗粒
IL175860B2 (en) A method of creating a solid pharmaceutical preparation for oral administration
JPH05201866A (ja) 配合製剤
CN101977593A (zh) 包含弱碱性药物以及有机酸的给药系统
JP3134187B2 (ja) 放出制御組成物
JP2011522050A (ja) バルサルタンのパルス放出
JP3677156B2 (ja) 医薬
EP1653932A1 (en) Modified release compositions for minocycline
JP5664225B2 (ja) 不快味マスキング粒子及びこれを含有する経口製剤
ES2516693T3 (es) Esferoides farmacéuticos
JP3929522B2 (ja) 難水溶性薬物の徐放性製剤
WO2005051362A2 (en) Oral benzimidazole compositions comprising an active core, an optional separating layer and an enteric coating
JP2002179554A (ja) 医 薬
JP2021084905A (ja) 経口医薬製剤およびその製造方法
Rhee et al. Controlled-release pelletized dosage forms using the extrusion-spheronization process

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050720

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070703